Pharma Pulse: SteinCares Partners to Expand Biosimilar Access in Latin America and Eli Lilly Issues Warning Over Compounded Tirzepatide Safety

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I’m your host, and let's get into today's headlines.

• SteinCares and Shilpa Biologicals have entered a licensing agreement to commercialize biosimilars in Latin America. Under the deal, SteinCares will manage regional registration and distribution, while Shilpa handles product development and long-term manufacturing to increase access to cost-effective biologics.
• In other news, Eli Lilly has released an open letter warning of potential safety risks associated with compounded tirzepatide mixed with Vitamin B12. Testing revealed significant impurity formation due to chemical incompatibility, which the company says introduces unknown toxicological risks. Consequently, Lilly has requested the FDA initiate a nationwide recall of products containing these untested additives.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.